For IPO Boutique's "scale of 1 to 5" BUY rating on Paratek Pharmaceuticals, Inc., and our comprehensive analysis, click the "Buy Market Research" link.
About Paratek Pharmaceuticals, Inc. (adapted from Paratek Pharmaceuticals, Inc. prospectus): Paratek is a pharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. Their lead product candidate, omadacycline, is a tetracycline-derived, broad-spectrum antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians.
This description is adapted from Paratek Inc. prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus..
Share this IPO Profile:
IPO Boutique aggregates information on public companies and private companies, such as Paratek Inc. "PRTK" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.